Charles River Laboratories International, Inc. (CRL) is joining the EASYGEN Consortium, a European Union-funded project aimed at accelerating the production of CAR-T cell therapies. The five-year initiative involves 18 partners across eight countries and is funded under grant agreement No 101194710 from the Innovative Health Initiative Joint Undertaking. The consortium’s main objective is to develop a fully automated platform to manufacture personalized cell therapies within 24 hours.
Since the announcement on August 26, CRL’s shares have decreased 0.2%, closing at $163.31. The company, with a market capitalization of $8.04 billion, is poised to enhance patient access to CAR-T therapies through a more efficient manufacturing process, addressing challenges like limited capacity and supply-chain delays. The global CAR-T cell therapy market is projected to grow at a 22.2% compound annual growth rate from $4.65 billion in 2024 through 2030.
